Search Medical Condition
Please enter condition
Please choose location from dropdown

OYS, Finland Clinical Trials

A listing of OYS, Finland clinical trials actively recruiting patients volunteers.

RESULTS

Found (78) clinical trials

Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology Triggers and Outcome

BACKGROUND: In industrialized countries a considerable and increasing proportion of strokes occur at younger ages. Stroke at young age causes marked disability at worst and thus long-standing socioeconomic consequences and exposes survivors for 4-fold risk of premature death compared with background population. Up to 50% of young patients with ischemic ...

Phase N/A

1.57 miles

Learn More »

Type 1 Diabetes Prediction and Prevention (DIPP) Study

Briefly, cord blood samples are collected and HLA-DR-DQ genotypes are determined from newborn babies. Families with a newborn baby carrying a DR-DQ genotype associated with increased risk for T1D are invited to participate in regular follow-up at the age of 3, 6, 9, 12, 18 and 24 months, and thereafter ...

Phase N/A

1.57 miles

Learn More »

Collagen Implant Compared to Gluteus Maximus Flap for Reconstruction of Pelvic Floor After ELAPE/EAPE in Rectal Cancer

Extended abdominoperineal excision (EAPE) of the rectum is the potentially curative operation for rectal carcinomas too low for primary anastomosis, especially if the levator and sphincter musculature is infiltrated. This enlarged operation, when the levator musculature is excised en bloc with the rectum, creates a large defect. Primary closure is ...

Phase

1.57 miles

Learn More »

Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax ) to the Drug (Everolimus) -Eluting Stent (Synergy ) in Acute Coronary Syndrome

Coronary artery disease (CAD) is the most frequent cause of death, accounting for approximately 13% of all deaths. In western countries, the incidence of ST-segment elevation myocardial infarction (STEMI) is around 77/100 000/year, whereas in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), the incidence is 132/100 000/year. Thus, the ...

Phase

1.57 miles

Learn More »

Outcome After Coronary Artery Bypass Grafting

Improvements in the surgical treatment of coronary artery disease are possible only when implementation of current methods and development of new methods are based on the solid ground of large and reliable clinical data. Furthermore, clinical findings assume even more significance when detected in study populations from different institutions with ...

Phase N/A

1.57 miles

Learn More »

Finnish Unicompartmental and Total Knee Arthroplasty Investigation

Background Knee osteoarthritis (OA) is a common joint disease, which may cause severe pain and lead to a reduced quality of life. It has been shown that the prevalence of symptomatic OA in those aged 60 and above was 9.6% in men and 18% in women. Primary treatment of knee ...

Phase N/A

1.57 miles

Learn More »

Estimation of the Minimal Important Difference and Validation of Foot and Ankle Instruments

Patients who are waiting for foot and ankle surgery are recruited from four large referral centers (Peijas Hospital, Seinjoki Central Hospital, Central Finland Central Hospital, Oulu University Hospital). Participants fill in foot and ankle-specific, generic and sosiodemographic questionnaires on the day of surgery, 6 months after surgery, and 6 months ...

Phase N/A

1.57 miles

Learn More »

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

Maintenance monotherapy with the potent polyadenosine 5'diphosphoribose [Poly (ADP-ribose)] polymerisation (PARP) inhibitor (PARPi) olaparib will significantly prolong progression-free survival (PFS) in platinum sensitive relapsed non-germline breast cancer susceptibility gene (BRCA) mutated ovarian cancer patients who are in complete or partial response following platinum based chemotherapy. Olaparib is a potent PARPi ...

Phase

1.57 miles

Learn More »

Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

This Nordic Myeloma Study Group study is phase 2 study for newly diagnosed transplant eligible myeloma patients between 18 - 70 years of age. Patients will have four IRd cycles of 28 day each as induction consisting of ixazomib 4 mg on days 1, 8 and 15 and lenalidomide 25 ...

Phase

1.57 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo-controlled study to investigate the safety and efficacy of MIN-117 in male and female patients with Major Depressive Disorder, aged 18 to 65 years. Approximately 324 patients will be randomly assigned to 1 of 3 treatment arms, including placebo, 5.0 mg MIN-117, or ...

Phase

1.57 miles

Learn More »